Why ANI Pharmaceuticals, Inc.’s (ANIP) Stock Is Down 7.67%
As of Friday, August 07, ANI Pharmaceuticals, Inc.’s ANIP share price has dipped by 7.67%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Commentary & Analysis
Why ANI Pharmaceuticals, Inc.’s (ANIP) Stock Is Down 5.21%
As of Monday, May 11, ANI Pharmaceuticals, Inc.’s ANIP share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why ANI Pharmaceuticals, Inc.’s (ANIP) Stock Is Up 8.20%
As of Monday, January 12, ANI Pharmaceuticals, Inc.’s ANIP share price has surged by 8.20%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ANI Pharmaceuticals, Inc.’s (ANIP) Stock Is Up 12.95%
As of Monday, January 12, ANI Pharmaceuticals, Inc.’s ANIP share price has surged by 12.95%, which has investors questioning if this is right time to sell.Tudor Pop
Why ANI Pharmaceuticals, Inc.’s (ANIP) Stock Is Down 5.60%
As of Friday, January 09, ANI Pharmaceuticals, Inc.’s ANIP share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ANIP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,504.1 | $609.5 | 50% |
|
| Shares Out (Mil) | 21.9 | 43.4 | 32% |
|
| Institutional Ownership | 94.9% | 83.9% | 66% |
|
| Float (Mil) | 19.7 | 45.7 | 28% |
|
| Beta | 0.46 | 0.73 | 26% |
|
| Avg Daily Volume (000s) | 324 | 309 | 53% |
|
| Price Change (52-week) |
(28.1%) | 64.9% | 27% |
|
| Growth | ANIP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 33.5% | 6.7% | 91% |
|
| Net Income (5yr) | 40.5% | (1.6%) | 91% |
|
| EPS (5yr) | 30.4% | 15.1% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 28.8% | (15.0%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | $2.165 | $9.288 | $10.485 | |
| Month Ago EPS | $2.199 | $9.294 | $10.536 | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $2.502 | $9.367 | $10.695 | |
| Year/Year Chg | 105.8% | 179.4% | 260.2% | |
| Financials | ANIP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $978 | $317 | 50% |
|
| Net Income (TTM) (Mil) | $108 | ($11) | 61% |
|
| EPS (TTM) | $4.809 | ($0.700) | 86% |
|
| Operating Cash Flow (TTM) (Mil) | $190 | ($7) | 58% |
|
| Net Cash Flow (TTM) (Mil) | $142 | $6 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $605 | $6 | 61% |
|
| Enterprise Value (Q1) (Mil) | $1,864 | $525 | 48% |
|
| Valuation | ANIP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.52 | 2.61 | 59% |
|
| P/E | 15.4 | 17.0 | 39% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.5 | 1.0 | 25% |
|
| Ratios | ANIP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.4% | 68.8% | 73% |
|
| Net Margin | 11.1% | 0.8% | 65% |
|
| ROA | 7.6% | (22.7%) | 81% |
|
| ROE | 21.0% | (22.8%) | 80% |
|
| Liabilities to Assets | 60.0% | 33.1% | 54% |
|
| F-Score | 7 | 3 | 82% |
|
ANI Pharmaceuticals, Inc. did not pass any screens on 9/11/2026.
